Alnuctamab: "Responses deepened over time, with CRS limited to low-grade, short-lived events (median duration 2 days)"; Multiple myeloma (Bristol-Myers Squibb) - Sep 15, 2023 - R&D Day
P1 data • Hematological Malignancies • Multiple Myeloma • Oncology
|